Einzeltreffer — DigiBib

Autism spectrum disorder (ASD) is a pervasive developmental disorder with gender differences. Oxytocin (OXT) is currently an important candidate drug for autism, but the lack of data on female autism is a big issue. It has been reported that the effect of OXT is likely to be different between male and female ASD patients. In the study, we specifically explored the role of the OXT signaling pathway in a VPA-induced female rat's model of autism. The data showed that there was an increase of either oxytocin or its receptor expressions in both the hippocampus and the prefrontal cortex of VPA-induced female offspring. To determine if the excess of OXT signaling contributed to autism symptoms in female rats, exogenous oxytocin and oxytocin receptor antagonists Atosiban were used in the experiment. It was found that exogenous oxytocin triggered autism-like behaviors in wild-type female rats by intranasal administration. More interestingly, several autism-like deficits including social interaction, anxiety, and repeat stereotypical sexual behavior in the VPA female offspring were significantly attenuated by oxytocin receptor antagonists Atosiban. Moreover, Atosiban also effectively improved the synaptic plasticity impairment induced by VPA in female offspring. Our results suggest that oxytocin receptor antagonists significantly improve autistic-like behaviors in a female rat model of valproic acid-induced autism.

Competing Interests: Competing interests The authors declare that they have no competing interests.

Titel:	Administration of Atosiban, an oxytocin receptor antagonist, ameliorates autistic-like behaviors in a female rat model of valproic acid-induced autism.
Autor/in / Beteiligte Person:	Liu, C ; Guo, Z ; Pang, J ; Zhang, Y ; Yang, Z ; Cao, J ; Zhang, T
Link:	Zum Volltext
Zeitschrift:	Behavioural brain research, Jg. 469 (2024-07-09), S. 115052
Veröffentlichung:	Amsterdam, Elsevier/North-Holland Biomedical Press., 2024
Medientyp:	academicJournal
ISSN:	1872-7549 (electronic)
DOI:	10.1016/j.bbr.2024.115052
Schlagwort:	Animals Female Rats Prefrontal Cortex drug effects Prefrontal Cortex metabolism Autism Spectrum Disorder chemically induced Autism Spectrum Disorder drug therapy Hippocampus drug effects Hippocampus metabolism Behavior, Animal drug effects Rats, Sprague-Dawley Neuronal Plasticity drug effects Social Interaction drug effects Sexual Behavior, Animal drug effects Anxiety drug therapy Anxiety chemically induced Pregnancy Valproic Acid pharmacology Receptors, Oxytocin antagonists & inhibitors Receptors, Oxytocin metabolism Disease Models, Animal Oxytocin pharmacology Oxytocin metabolism Oxytocin administration & dosage Vasotocin analogs & derivatives Vasotocin pharmacology Autistic Disorder chemically induced Autistic Disorder drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Behav Brain Res] 2024 Jul 09; Vol. 469, pp. 115052. <i>Date of Electronic Publication: </i>2024 May 22. MeSH Terms: Valproic Acid* / pharmacology ; Receptors, Oxytocin* / antagonists & inhibitors ; Receptors, Oxytocin* / metabolism ; Disease Models, Animal* ; Oxytocin* / pharmacology ; Oxytocin* / metabolism ; Oxytocin* / administration & dosage ; Vasotocin* / analogs & derivatives ; Vasotocin* / pharmacology ; Autistic Disorder* / chemically induced ; Autistic Disorder* / drug therapy ; Animals ; Female ; Rats ; Prefrontal Cortex / drug effects ; Prefrontal Cortex / metabolism ; Autism Spectrum Disorder / chemically induced ; Autism Spectrum Disorder / drug therapy ; Hippocampus / drug effects ; Hippocampus / metabolism ; Behavior, Animal / drug effects ; Rats, Sprague-Dawley ; Neuronal Plasticity / drug effects ; Social Interaction / drug effects ; Sexual Behavior, Animal / drug effects ; Anxiety / drug therapy ; Anxiety / chemically induced ; Pregnancy Contributed Indexing: Keywords: Autism; Female; Oxytocin; Oxytocin receptor antagonists; Valproic acid Substance Nomenclature: 614OI1Z5WI (Valproic Acid) ; 0 (Receptors, Oxytocin) ; 081D12SI0Z (atosiban) ; 50-56-6 (Oxytocin) ; W6S6URY8OF (Vasotocin) Entry Date(s): Date Created: 20240523 Date Completed: 20240606 Latest Revision: 20240614 Update Code: 20240614

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Administration of Atosiban, an oxytocin receptor antagonist, ameliorates autistic-like behaviors in a female rat model of valproic acid-induced autism.